NCT01085266View on ClinicalTrials.gov

An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease

PHASE3TerminatedINTERVENTIONAL
Enrollment

362

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

June 30, 2011

Conditions
Huntington Disease
Interventions
DRUG

Dimebon (latrepirdine)

Sponsors

Lead Sponsor

Medivation, Inc.

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Medivation, Inc.

INDUSTRY

NCT01085266 - An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease | Biotech Hunter | Biotech Hunter